All State Journal

Delveinsight Business Research LLP

“Prader-Willi Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Prader-Willi Syndrome Market. 

The Prader-Willi Syndrome Pipeline report embraces in-depth commercial, regulatory, and Prader-Willi Syndrome clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Prader-Willi Syndrome drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Prader-Willi Syndrome Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for Prader-Willi Syndrome treatment and the aggregate therapies developed by major pharma companies.

• It accesses the different Prader-Willi Syndrome therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the major Prader-Willi Syndrome companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the Prader-Willi Syndrome drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Prader-Willi Syndrome therapeutic market.

Analysis of Emerging Prader-Willi Syndrome Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Prader-Willi Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Learn How the Prader-Willi Syndrome Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

Prader-Willi Syndrome Therapeutics Landscape

There are approx. 18+ key companies are developing therapies for Prader-Willi Syndrome. Currently, Soleno Therapeutics is leading the therapeutics market with its Prader-Willi Syndrome drug candidates in the most advanced stage of clinical development.

“On June 13, 2023, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in Prader-Willi syndrome (PWS). Acadia acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.”

Prader-Willi Syndrome Companies Actively Working in the Therapeutic Market Include:

• Soleno Therapeutics

• Levo Therapeutics

• Inversago Pharma

• Saniona

• LG Life Sciences

• GLWL Research

• OptiNose

• Larimar Therapeutics

• Helsinn

• ConSynance Therapeutics

• Neuren Pharmaceuticals

• Radius Health

• Rhythm

• Tonix Pharmaceuticals

Emerging and Marketed Prader-Willi Syndrome Drugs Covered in the Report Include:

• Diazoxide choline controlled release (DCCR): Soleno Therapeutics

• Intranasal carbetocin (LV-101): Levo Therapeutics

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Prader-Willi Syndrome Companies Working in the Market @ 

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Prader-Willi Syndrome Treatment Patterns

4. Prader-Willi Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Prader-Willi Syndrome Late Stage Products (Phase-III)

7. Prader-Willi Syndrome Mid-Stage Products (Phase-II)

8. Prader-Willi Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Prader-Willi Syndrome Discontinued Products

13. Prader-Willi Syndrome Product Profiles

14. Major Prader-Willi Syndrome Companies in the Market

15. Key Products in the Prader-Willi Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Prader-Willi Syndrome Unmet Needs

18. Prader-Willi Syndrome Future Perspectives

19. Prader-Willi Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Acute Lymphoblastic Leukemia (ALL) Market

“Acute Lymphoblastic Leukemia (ALL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Lymphoblastic Leukemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/